Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$14.19 USD
+0.22 (1.57%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $14.18 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Company Summary
Tampa, FL-based Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience in April 2019.
The company’s flagship product Exparel was launched in 2012. Exparel is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. In 2012, the company signed a licensing ...
Company Summary
Tampa, FL-based Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience in April 2019.
The company’s flagship product Exparel was launched in 2012. Exparel is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. In 2012, the company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications. In 2017, Pacira signed an agreement with DePuy Synthes Sales Inc. (a subsidiary of J&J) to market and promote the use of Exparel for orthopedic procedures in the United States market. Notably, in July 2020, Pacira concluded its partnership agreement with DePuy Synthes Sales.
The acquisition of MyoScience also added iovera, a hand-held medical device used to deliver a precise, controlled application of cold temperature to targeted nerves, to Pacira’s portfolio. The company sells this product directly to end users.
The acquisition of Flexion Therapeutics, Inc in November 2021, gave Pacira its second marketed product, Zilretta. Zilretta received FDA approval in October 2017 as the first and only extended-release, intra-articular therapy for osteoarthritis (OA) knee pain and was launched in the United States, shortly thereafter.
Pacira’s Exparel, Zilretta and the iovera drug delivery system are highly complementary products that provide patients with long-acting, non-opioid therapies for pain management.
In 2023, Pacira acquired PCRX-201 (enekinragene inzadenovec) from a Germany-based privately held company, GQ Bio Therapeutics GmbH. PCRX-201 is being developed to treat osteoarthritis of the knee.
For full-year 2023, Pacira generated total revenues of $675 million compared with $666.8 million recorded in 2022.
General Information
Pacira BioSciences, Inc
5401 WEST KENNEDY BOULEVARD SUITE 890
TAMPA, FL 33609
Phone: 813-553-6680
Fax: 302-655-5049
Email: susan.mesco@pacira.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.74 |
Current Year EPS Consensus Estimate | 3.07 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 13.97 |
52 Week High | 37.94 |
52 Week Low | 11.16 |
Beta | 0.88 |
20 Day Moving Average | 1,689,141.75 |
Target Price Consensus | 20.11 |
4 Week | -29.16 |
12 Week | -53.22 |
YTD | -57.94 |
4 Week | -31.36 |
12 Week | -56.18 |
YTD | -64.55 |
Shares Outstanding (millions) | 46.13 |
Market Capitalization (millions) | 654.54 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 4.62 |
Trailing 12 Months | 4.55 |
PEG Ratio | NA |
vs. Previous Year | 4.92% |
vs. Previous Quarter | 52.38% |
vs. Previous Year | 5.05% |
vs. Previous Quarter | 6.53% |
Price/Book | 0.74 |
Price/Cash Flow | 3.58 |
Price / Sales | 0.95 |
6/30/24 | 13.22 |
3/31/24 | 12.98 |
12/31/23 | 12.81 |
6/30/24 | 7.24 |
3/31/24 | 7.08 |
12/31/23 | 6.80 |
6/30/24 | 6.82 |
3/31/24 | 5.81 |
12/31/23 | 5.24 |
6/30/24 | 5.70 |
3/31/24 | 4.78 |
12/31/23 | 4.17 |
6/30/24 | 16.63 |
3/31/24 | 16.20 |
12/31/23 | 15.56 |
6/30/24 | 9.21 |
3/31/24 | 10.34 |
12/31/23 | 6.22 |
6/30/24 | 14.56 |
3/31/24 | 14.93 |
12/31/23 | 9.14 |
6/30/24 | 19.06 |
3/31/24 | 19.18 |
12/31/23 | 18.74 |
6/30/24 | 1.79 |
3/31/24 | 1.88 |
12/31/23 | 1.91 |
6/30/24 | 0.67 |
3/31/24 | 0.57 |
12/31/23 | 0.59 |
6/30/24 | 40.13 |
3/31/24 | 36.45 |
12/31/23 | 37.13 |